Cullinan Management’s Promising Pipeline and Strategic Collaborations Drive Buy Rating
I'm PortAI, I can summarize articles.
Soumit Roy from JonesTrading has maintained a Buy rating on Cullinan Management with a price target of $34.00, citing promising developments in its pipeline, including the CLN-978 T-cell engager in Phase 1 trials and collaboration with Taiho on the Zipalertinib program. Initial data for CLN-978 is expected in 2026, while a New Drug Application filing for Zipalertinib is anticipated by the end of 2025. H.C. Wainwright also reiterated a Buy rating with a $24.00 price target, reflecting confidence in Cullinan's innovative therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments